Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DBVT NASDAQ:KERN NASDAQ:SKIN NYSE:VOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDBVTDBV Technologies$9.52+1.3%$9.80$2.20▼$12.78$257.51M-0.3628,039 shs29,657 shsKERNAkerna$5.89$0.17▼$6.40$64.92M3.02339,022 shs70,795 shsSKINBeauty Health$2.30-5.7%$1.98$0.78▼$2.56$309.45M1.23874,453 shs1.35 million shsVORVor Biopharma$1.80-10.4%$2.12$0.13▼$3.29$228.03M2.057.65 million shs6.04 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDBVTDBV Technologies+7.69%-0.40%-4.28%+7.80%+140.99%KERNAkerna0.00%0.00%0.00%0.00%0.00%SKINBeauty Health+4.72%+22.00%+29.10%+53.46%+80.74%VORVor Biopharma+1.52%-1.47%-2.90%+813.64%+84.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDBVTDBV Technologies$9.52+1.3%$9.80$2.20▼$12.78$257.51M-0.3628,039 shs29,657 shsKERNAkerna$5.89$0.17▼$6.40$64.92M3.02339,022 shs70,795 shsSKINBeauty Health$2.30-5.7%$1.98$0.78▼$2.56$309.45M1.23874,453 shs1.35 million shsVORVor Biopharma$1.80-10.4%$2.12$0.13▼$3.29$228.03M2.057.65 million shs6.04 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDBVTDBV Technologies+7.69%-0.40%-4.28%+7.80%+140.99%KERNAkerna0.00%0.00%0.00%0.00%0.00%SKINBeauty Health+4.72%+22.00%+29.10%+53.46%+80.74%VORVor Biopharma+1.52%-1.47%-2.90%+813.64%+84.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDBVTDBV Technologies 2.80Moderate Buy$14.7554.94% UpsideKERNAkerna 0.00N/AN/AN/ASKINBeauty Health 2.00Hold$2.6314.13% UpsideVORVor Biopharma 2.56Moderate Buy$6.07237.04% UpsideCurrent Analyst Ratings BreakdownLatest KERN, VOR, SKIN, and DBVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.008/1/2025SKINBeauty HealthStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$3.00 ➝ $4.006/30/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$3.006/26/2025DBVTDBV TechnologiesLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/26/2025DBVTDBV TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$21.006/26/2025VORVor BiopharmaWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Outperform(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDBVTDBV Technologies$4.15M62.85N/AN/A$1.42 per share6.70KERNAkerna$13.65M0.00N/AN/A($1.52) per share0.00SKINBeauty Health$334.30M0.87$0.06 per share38.59$0.41 per share5.61VORVor BiopharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDBVTDBV Technologies-$113.92M-$4.77N/AN/AN/A-3,220.49%-287.15%-138.83%11/5/2025 (Estimated)KERNAkerna-$79.06M-$7.10N/AN/AN/A-339.99%N/A-113.03%N/ASKINBeauty Health-$29.10M-$0.28N/AN/AN/A-6.13%-32.82%-2.96%11/11/2025 (Estimated)VORVor BiopharmaN/A-$13.66N/AN/AN/AN/AN/AN/AN/ALatest KERN, VOR, SKIN, and DBVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025SKINBeauty Health-$0.06$0.03+$0.09$0.03$74.67 million$78.20 million7/29/2025Q2 2025DBVTDBV Technologies-$0.21-$1.55-$1.34-$1.55$0.64 million$1.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDBVTDBV TechnologiesN/AN/AN/AN/AN/AKERNAkernaN/AN/AN/AN/AN/ASKINBeauty HealthN/AN/AN/AN/AN/AVORVor BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDBVTDBV TechnologiesN/A2.452.45KERNAkernaN/A0.100.10SKINBeauty Health4.915.154.15VORVor BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDBVTDBV Technologies71.74%KERNAkerna21.97%SKINBeauty Health93.26%VORVor Biopharma97.29%Insider OwnershipCompanyInsider OwnershipDBVTDBV Technologies1.44%KERNAkerna1.20%SKINBeauty Health41.00%VORVor Biopharma0.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDBVTDBV Technologies8027.40 million27.00 millionOptionableKERNAkerna11210.35 million10.23 millionNo DataSKINBeauty Health1,030126.82 million74.83 millionOptionableVORVor Biopharma140126.68 million65.45 millionNot OptionableKERN, VOR, SKIN, and DBVT HeadlinesRecent News About These CompaniesWe Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth CarefullySeptember 7 at 6:44 PM | finance.yahoo.comOMERS ADMINISTRATION Corp Takes Position in Vor Biopharma Inc. $VORSeptember 7 at 4:12 AM | marketbeat.comVor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 400,000 SharesSeptember 6, 2025 | insidertrades.comVor Bio Appoints Adi Osovsky, S.J.D. as General CounselSeptember 2, 2025 | globenewswire.comVor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 806,351 SharesSeptember 1, 2025 | americanbankingnews.comInsider Selling: Vor Biopharma (NYSE:VOR) Major Shareholder Sells 611,647 Shares of StockAugust 30, 2025 | insidertrades.comVor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 284,190 SharesAugust 28, 2025 | insidertrades.comVor Biopharma shares rise after collaborator’s IgAN therapy meets Phase 3 endpointAugust 28, 2025 | msn.comTelitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA NephropathyAugust 27, 2025 | globenewswire.comVor Bio to Participate in Upcoming Investor ConferencesAugust 26, 2025 | globenewswire.comVor Biopharma Inc. (NYSE:VOR) Receives Consensus Recommendation of "Moderate Buy" from AnalystsAugust 26, 2025 | marketbeat.comVor Biopharma: Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 19, 2025 | finanznachrichten.deQ3 EPS Estimates for Vor Biopharma Reduced by HC WainwrightAugust 19, 2025 | marketbeat.comVor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 18, 2025 | globenewswire.comAnalysts Set Expectations for Vor Biopharma FY2028 EarningsAugust 17, 2025 | marketbeat.comWedbush Brokers Boost Earnings Estimates for Vor BiopharmaAugust 17, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Receives "Buy" Rating from HC WainwrightAugust 16, 2025 | marketbeat.comVor Biopharma Shares Soar on Positive Results for Autoimmune-Disorder TreatmentAugust 13, 2025 | marketwatch.comVor says drug licensed from RemeGen succeeded in Sjögren’s studyAugust 13, 2025 | finance.yahoo.comVor Bio Rallies On Strong Data For Autoimmune Drug CandidateAugust 13, 2025 | benzinga.comTelitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL InhibitorAugust 13, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025Big Rallies Brewing? 3 Analyst Favorites to Watch CloselyBy Nathan Reiff | August 18, 2025Big Analyst Revisions Could Be Ahead for SoFi StockBy Gabriel Osorio-Mazilli | August 26, 2025Shopify’s Risk-Reward Profile Is Suddenly Red HotBy Sam Quirke | August 22, 2025KERN, VOR, SKIN, and DBVT Company DescriptionsDBV Technologies NASDAQ:DBVT$9.59 +0.19 (+1.97%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Akerna NASDAQ:KERNAkerna Corp. provides enterprise software solutions that enable regulatory compliance and inventory management in the United States and Canada. The company offers MJ Platform for the cannabis, hemp, and CBD industry; and Leaf Data Systems, a government regulatory software. It also provides consulting services to cannabis industry; business intelligence, data analytics and other software related services; and Last Call Analytics, a retail analytics platform. In addition, the company operates Solo, a seed-to-sale tagging and tracking software platform, and Trellis, a cultivation and compliance software platform. Akerna Corp. was founded in 2010 and is headquartered in Denver, Colorado.Beauty Health NASDAQ:SKIN$2.30 -0.14 (-5.74%) Closing price 04:00 PM EasternExtended Trading$2.28 -0.02 (-0.87%) As of 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.Vor Biopharma NYSE:VOR$1.80 -0.21 (-10.45%) Closing price 04:00 PM EasternExtended Trading$1.82 +0.02 (+1.06%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
